11210 research outputs found
Sort by
Methinks AI software for identifying large vessel occlusion in non-contrast head CT: A pilot retrospective study in American population
No full textBackground: Non-contrast computed tomography (NCCT) is the first image for stroke assessment, but its sensitivity for detecting large vessel occlusion (LVO) is limited. Artificial intelligence (AI) algorithms may contribute to a faster LVO diagnosis using only NCCT. This study evaluates the performance and the potential diagnostic time saving of Methinks LVO AI algorithm in a U.S. multi-facility stroke network.
Methods: This retrospective pilot study reviewed NCCT and computed tomography angiography (CTA) images between 2015 and 2023. The Methinks AI algorithm, designed to detect LVOs in the internal carotid artery and middle cerebral artery, was tested for sensitivity, specificity, and predictive values. A neuroradiologist reviewed cases to establish a gold standard. To evaluate potential time saving in workflow, time gaps between NCCT and CTA were analyzed and stratified into four groups in true positive cases: Group 1 (60 min).
Results: From a total of 1155 stroke codes, 608 NCCT exams were analyzed. Methinks LVO demonstrated 75% sensitivity and 83% specificity, identifying 146 out of 194 confirmed LVO cases correctly. The PPV of the algorithm was 72%. The NPV was 83% (considering \u27other occlusion\u27, \u27stenosis\u27 and \u27posteriors\u27 as negatives), and 73% considered the same conditions as positives. Among the true positive cases, we found 112 patients Group 1, 32 patients in Group 2, 15 patients in Group 3, 3 patients in Group 4.ConclusionThe Methinks AI algorithm shows promise for improving LVO detection from NCCT, especially in resource limited settings. However, its sensitivity remains lower than CTA-based systems, suggesting the need for further refinement
Pertuzumab plus trastuzumab (P+T) in patients (pts) with bladder (BC) and ovarian cancer (OC) with ERBB2/3 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
No full textLong-term follow-up of left atrial appendage exclusion: Results of the V-CLIP multi-center post-market study
No full textBackground: Cardiac surgery patients with pre- or post-operative atrial fibrillation are at an increased risk for thromboembolic stroke, often due left atrial appendage (LAA) thrombus. Surgical LAA exclusion (LAAE) can be performed and must be complete to avoid increased thrombus formation. Methods: This prospective, multi-center, post-market study (NCT05101993) evaluated the long-term safety and performance of the epicardial V-shape AtriClip device. Patients ≥18 years who had received V-shape AtriClip devices during non-emergent cardiac surgery consented to a prospective 12-month follow-up visit and LAA imaging. The primary performance was LAAE without residual left atrium-LAA communication, assessed by imaging at the last follow-up visit. The primary safety was device- or implant procedure-related serious adverse events (SAEs) (death, major bleeding, surgical site infection, pericardial effusion requiring intervention, myocardial infarction) within 30 days. Results: Of 155 patients from 11 U.S. centers, 151 patients had evaluable imaging. Complete LAAE was obtained in all patients. Primary performance in the intent-to-treat population was met, with 97% (95% CI 93.52%, 99.29%; p = 0.0001) complete LAAE. Primary safety was met, with 100% (95% CI 97.75%, 100%; p \u3c 0.0001) of patients free from pre-defined SAEs within 30 days. One device-related SAE was reported, which resolved intraprocedurally. Conclusions: AtriClip V-Clip showed safe and successful LAAE through 12 months of follow-up
Illinois Masonic Medical Center House Staff Directory, 2004-2005
No full textIllinois Masonic Medical Center, Chicago, IL: House staff directory with photos of IMMC residents in 2004-2005 for the specialties of anesthesiology, cardiac electrophysiology, cardiology, dentistry, emergency medicine, family practice, internal medicine, obstetrics and gynecology, osteopathic rotating internship, pathology, podiatry, radiology, general surgery, and surgical critical care.https://institutionalrepository.aah.org/alldocuments/2174/thumbnail.jp
Illinois Masonic Medical Center House Staff, 1991-92
No full textIllinois Masonic Medical Center, Chicago, IL: House staff roster with photos of IMMC residents in 1991-1992 for the specialties of anesthesiology, cardiology, dentistry, emergency medicine, internal medicine, obstetrics and gynecology, pathology, podiatry, radiology, general surgery, and transitional year.https://institutionalrepository.aah.org/alldocuments/2163/thumbnail.jp
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: A biomarker analysis from the PACE phase II study
No full textPurpose: Circulating tumor cells (CTCs) are biomarkers associated with poor prognosis and treatment resistance in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC). This analysis evaluates the prognostic role of baseline CTC enumeration and its interaction with treatment regimens in patients progressing on CDK4/6 inhibitors.
Experimental design: The PACE trial is a phase II, multicenter, randomized study of HR+/HER2- MBC patients experiencing progression on aromatase inhibitors (AI) and CDK4/6 inhibitors. Patients were randomized 1:2:1 to receive fulvestrant (F), F+palbociclib (F+P), or F+P+avelumab (F+P+A). Baseline CTCs were enumerated using CellSearch™ with a threshold of ≥5 CTCs/7.5 mL to classify patients as StageIV indolent or StageIV aggressive. Concurrent ctDNA analysis was performed using Guardant360®. Progression-free survival (PFS) was the primary endpoint.
Results: Among 220 randomized patients, 203 were evaluable for baseline CTCs; 76% had detectable CTCs, and 49% were StageIV aggressive. Patients with de novo MBC were more frequently StageIV aggressive (47.5% vs. 30.8%). Baseline CTCs were prognostic, with median PFS of 5.7 months for StageIV indolent and 3.5 months for StageIV aggressive patients (HR 1.69, 90% CI 1.27-2.24, P
Conclusions: Baseline CTC enumeration provides significant prognostic information in HR+/HER2- MBC. StageIV aggressive patients derive greater benefit from F+P or F+P+A over F alone, independent of clinical or ctDNA features. This highlights the potential of to guide treatment decision-making